Navigation Links
SinoFresh(R) Nasal Spray Kills MRSA 'Super-Bug' in Live Noses

SinoFresh(R) Passes First Key Test for Potential to Control 'Super-Bug'


VENICE, Fla., Aug. 19 /PRNewswire-FirstCall/ -- SinoFresh HealthCare, Inc., (OTC Bulletin Board: SFSH) announced preliminary results today from a successful in vivo pilot study indicating that its patented SinoFresh(R) nasal spray was shown to be useful in controlling the MRSA "super-bug" in the nasal passages. This study utilized a recognized scientific model intended to demonstrate SinoFresh(R) nasal spray's ability to kill MRSA hiding in the nasal passages. These favorable efficacy results follow an earlier, successful in vitro study that was conducted at the Public Health Research Institute under the direction of Dr. Barry Kreiswirth, director of the Tuberculosis Center and Hospital Infections Program.

The study showed that "SinoFresh(R) nasal spray used three times daily appeared to effectively eliminate MRSA in the noses of the test animals while leaving enough normal microbes to keep a normal population in the nasal passages," according to Dr. John Todhunter, consultant to SinoFresh, who oversaw the study conducted at Virion Systems in Rockville, MD.

MRSA (which stands for Methicillin Resistant Staphylococcus aureus) is a growing concern in the health care community. It incubates in the nasal passages and then gets on the skin where it can cause severe, virulent infections. The effect of MRSA can lead to disfigurement and sometimes death. MRSA is also highly antibiotic resistant, making MRSA infections difficult to treat. It is believed that approximately 2 - 3 million persons in the U.S. walk around carrying MRSA in their nasal passages at any time and elimination or severe reduction of nasal MRSA colonies is seen as a potentially important weapon in fighting the spread of MSRA. The antibiotic Mupirocin is currently used to reduce nasal MRSA loads.

SinoFresh(R) nasal spray attacks MRSA in the nasal passages by destroying the "super-bug's" cell walls and membranes by physical means rather than by an antibiotic mechanism involving attack on the metabolism of the microbes as occurs with the use of antibiotics. "Since bacteria can in effect change their metabolism to be resistant to antibiotics, but can't very well change the laws of physics the chances for development of resistance to SinoFresh(R) Nasal Spray's mode of killing them is much lower said Dr. Todhunter."

According to William Wilferth, VP for Research and Development at SinoFresh, "These results have exceeded our expectations. The positive results of this in vivo study gives us the solid scientific platform we have needed in order to advance our efforts to fight MRSA to the next level."

Charles Fust, CEO of SinoFresh, noted that the data reported is extremely encouraging and that there is a significant market need for new methods to address MRSA control which is believed to be as many as 80 to 100 million treatments annually in the United States alone.

About SinoFresh HealthCare, Inc.

SinoFresh HealthCare, Inc. (OTC BB: SFSH.OB - News) is a developer and marketer of innovative upper respiratory system therapies. The company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms that are suspected to cause pathogenesis of the mouth, nose and throat. The company's lead product, SinoFresh(R) Nasal and Sinus Care, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The company is also researching how antiseptic cleansing may alleviate chronic sinus distress, a condition that may affect 37 million Americans annually. SinoFresh(R) products are available in major retail outlets nationwide. More information is available at


William Wilferth, R. Ph. M.S.

VP Research & Development

SinoFresh HealthCare, Inc.

787 Commerce Drive / Suite 6

Venice, FL 34292

Tel: (941) 488-9090 / e-mail:

SOURCE SinoFresh HealthCare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nasal Anthrax Vaccine Proves Effective in Animal Study
2. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
3. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
4. Nosefrida Nasal Aspirator - A Parents Alternative to Medicines on the Verge of FDA Ban
5. As Cold & Flu Season Nears, New Baby Nasal Aspirator Offers Safe and Effective Alternative to FDA-Discouraged Medicines
6. U.S. Advisers OK Nasal Spray Flu Vaccine for Young Children
7. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
8. Saline Irrigation Eases Chronic Nasal Symptoms
9. Protein Nasal Spray Revives Sleep-Deprived Monkeys
10. Saline Nasal Wash Helps Kids Fight Colds, Flu
11. Nasal polyps from analgesics
Post Your Comments:
(Date:6/26/2016)... , ... June 27, 2016 , ... Quality metrics are ... in many ways they remain in the eye of the beholder, according to experts ... publication of The American Journal of Managed Care. For the full issue, click ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: